BioLight Announces First IOPtiMate™ System Sale in Hungary

TEL AVIV, Israel, April 13, 2015 /PRNewswire/ --

BioLight Life Sciences Investments Ltd.  (TASE: BOLT)(OTCQX:  BLGTY), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, today announced the first sale of the IOPtiMate™ system to a medical center located in Hungary.

The IOPtiMate™ system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.

"We are pleased that a medical center in Hungary has selected the IOPtiMate™ system as its glaucoma surgery solution and believe that this provides further validation of this unique technology from the ophthalmology community," said Suzana Nahum-Zilberberg, BioLight's chief executive officer.  "Recent first sales in Hong Kong and Poland, additional distribution agreements in new territories for the IOPtiMate™ system and its launch in China, further demonstrates our ability to become a truly global player in this marketplace."

The sale of the first system in Hungary is a result of a marketing campaign to leading physicians and medical centers mainly in Asia and Europe for the IOPtiMate™ system as part of the company's focus on markets with unmet needs for better solutions to treat glaucoma. These marketing efforts have recently resulted in first sales of the IOPtiMate™ system in Hong Kong and Poland, as well as distribution agreements in Peru and Belarus.

BioLight recently announced a strategic partnership agreement with Rock-One International Holdings Ltd. The agreement will help BioLight maximize its presence in the Chinese market, the second largest healthcare market in the world after the U.S.

About BioLight 

BioLight Life Sciences Investments invests in, manages and commercializes biomedical innovations grouped around defined medical conditions - ophthalmology and cancer diagnostics. The ophthalmic technologies include IOPtiMate™, a laser-based non-invasive surgical treatment for glaucoma; TeaRx™, a point-of-care multi-parameter diagnostic test for dry-eye syndrome; Eye-D®, a controlled release drug-delivery insert platform and a new technology a drug-delivery platform for the improvement of ocular molecule transmission; and OphRx, a drug delivery technology platform for ocular uses. The cancer diagnostic activities include tests that are designated for bladder, cervical, multiple myeloma and other cancers.

Leading key investors, holding about 45% of BioLight's shares, are Mr. Israel Makov, Chairman of Sun Pharmaceuticals, former CEO and President of Teva Pharmaceuticals and former Chairman of Given Imaging, Mr. Dilip Shanghvi, founder of Sun Pharmaceuticals, India's largest pharmaceutical company, and Mr. Dan Oren, founder and CEO of Dexcel Pharma, the second-largest pharmaceutical manufacturer in Israel.

For more information please visit the Company's website at http://www.bio-light.co.il.

CONTACTS:
BioLight
Itai Bar-Natan, CFO
[email protected]
Tel: +972-73-2753400

SOURCE BioLight Life Sciences Investments Ltd.